Patent ID: 8178580

Claim:
A method of treating a patient suffering from AA amyloidosis and having renal impairment comprising measuring a first creatinine clearance rate of the patient and determining it to be (a) less than about 30 mL/min, (b) from about 30 to about 80 mL/min or (c) greater than about 80 mL/min, and orally administering to said patient, in dependence on which rate is found, respectively, (a), a dose of 400 mg twice a day of an active agent which is 1,3-propane disulfonic acid or a pharmaceutically acceptable salt thereof, in a formulation with a pharmaceutically acceptable carrier, such that when said dose is orally administered to said patient for multiple administrations, a mean C max after a single administration of about 500-2,000 ng/mL±20% is achieved; (b), dose of 800 mg twice a day of said active agent in a formulation with a pharmaceutically acceptable carrier, such that when said dose is orally administered to said patient for multiple administrations, a mean C max after a single administration of about 500-2,000 ng/mL±20% is achieved; or (c), a dose of 1200 mg twice a day of said active agent, in a formulation with a pharmaceutically acceptable carrier, such that when said dose is orally administered to said patient for multiple administrations, a mean C max after a single administration of about 500-2,000 ng/mL±20% is achieved; and measuring a second creatinine clearance rate of said patient and determining it to be in a different rate range (a), (b) or (c), as defined above, from said first creatinine clearance rate, and orally administering to said patient an active agent dose (a), (b) or (c) as defined above, corresponding to said different rate.